fiercepharmaSeptember 06, 2017
Tag: VBI , vaccines , BiondVax
> VBI Vaccines won FDA approval for its phase 3 program of hep B shot Sci-B-Vac. Enrollment is expected to start this year in the U.S., Europe and Canada. The vaccine is already licensed in Israel and 14 other countries. Release
> AMAL Therapeutics raised €8 million to advance its experimental colorectal cancer vaccine into human testing. Labiotech.eu story
> BiondVax, which is working on a universal flu vaccine candidate, voluntarily delisted from the Tel Aviv Stock Exchange. The company is still listed on Nasdaq. Release
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: